Hypersensitivity to the active substance or to any of the excipients listed in Description.
Known hypersensitivity to sulphonamides.
Active peptic ulceration or gastrointestinal (GI) bleeding.
Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
In pregnancy and in women of childbearing potential unless using an effective method of contraception (see Interactions). Celecoxib has been shown to cause malformations in the two animal species studied (see Use in Pregnancy & Lactation and Pharmacology: Toxicology: Preclinical safety data under Actions). The potential for human risk in pregnancy is unknown, but cannot be excluded.
Breast feeding (see Use in Pregnancy & Lactation and Pharmacology: Toxicology: Preclinical safety data under Actions).
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥ 10).
Patients with estimated creatinine clearance <30 ml/min.
Inflammatory bowel disease.
Congestive heart failure (NYHA II-IV).
Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see Precautions).